Delving into the Latest Updates on Recombinant staphylokinase-hirudin fusion protein(Academy of Military Medical Sciences) with Synapse

Overview

Basic Info

Drug Type

Fusion protein

Synonyms-

Target

PLG x prothrombin x uPA

Action

stimulants, inhibitors

Mechanism

PLG stimulants(Plasminogen stimulants), prothrombin inhibitors(Prothrombin inhibitors), uPA stimulants(Urokinase plasminogen activator stimulants)

Therapeutic Areas

Cardiovascular Diseases

Active Indication-

Inactive Indication

Thromboembolism

Originator Organization

Academy of Military Medical Sciences

Active Organization-

Inactive Organization

Wuhan Optical Valley Humanwell Biological Pharmaceutical Co.

Academy of Military Medical Sciences

Drug Highest PhasePendingIND Application

First Approval Date-

Regulation-

Login to view timeline

A pure recombinant staphylokinase-hirudin fusion protein (SFH) was obtained by recombinant genetic engineering and purification techniques. The thrombolytic and anticoagulant activities of SFH were investigated using in vitro coagulation models and chromogenic assays. The results showed that intact SFH had targeted thrombolytic activity, and gained anticoagulant activity when cleaved by FXa. In addition, we investigated the pharmacodynamics of SFH in vivo using a variety of animal models, including a rat inferior vena cava thrombosis model, a rat coronary thrombosis model, a rabbit carotid artery thrombosis model and a canine coronary thrombosis model. We found that SFH had an obvious thrombolytic effect and could prevent and reduce re-embolization after thrombolysis and reduce the serious bleeding side effects caused by the combination of thrombolytic and anticoagulant drugs. The results suggest that SFH can be used for thrombolytic therapy in thromboembolic diseases.

100 Deals associated with Recombinant staphylokinase-hirudin fusion protein(Academy of Military Medical Sciences)

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Thromboembolism	IND Application	China	Wuhan Optical Valley Humanwell Biological Pharmaceutical Co.	03 Apr 2013
Thromboembolism	IND Application	China	Academy of Military Medical Sciences	03 Apr 2013

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.

login

or

view full example data

Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.

login

or

view full example data

Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.

login

or

view full example data

Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.

login

or

view full example data

Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.

login

or

view full example data

Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

login

or

view full example data